AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 281 min read$ARQT

Curran Terrie sold $956K of ARQT

Curran Terrie sold 38,200 shares of Arcutis Biotherapeutics, Inc. (ARQT) at $25.03 ($0.96M total) across 2 trades on 2026-08-27.

Original reporting
SEC EDGAR · Curran Terrie
Published Aug 28, 2026, 9:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 28, 2026, 9:52 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ARQT
Neutral
medium confidence
Mentioned
$ARQT
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARQTNeutralLow
01

Why it matters

The transaction is a primary disclosure but small in scale, offering limited trading insight.

02

Market read

Minor insider sale with low materiality; unlikely to move the stock significantly.

03

What to watch

Potential upcoming clinical data releases or financing needs that prompted the director to liquidate shares.

Relevance 5/10Novelty 5/10Timing: post-market today

Background

Form 4 filing discloses insider transactions; this is the first public report of the sale.

Company-level read

Ticker impact

$ARQTNeutralMedium confidence
Context

Director Curran Terrie sold 38,200 shares for $956K on 2026-08-27, reducing his holding to 23,526 shares.

Expected impact

Minimal short-term price effect; may cause slight downward pressure if aggregated with other insider sales.

Evidence & confidence

A $956K sale by a director is a routine liquidity event; the size is not material for a mid‑cap biotech, so market reaction is likely muted.

Market effects

Sector

No broader sector impact; biotech peers unlikely to be affected.

Regional

Limited to US biotech market, negligible.

Global

None

Counterpoint

What could challenge this read

The sale could be interpreted as a red flag if multiple insiders sell around the same time.

Key entities

  • Company
    Arcutis Biotherapeutics, Inc.

    Biotech firm developing dermatology therapies, ticker ARQT.

  • Insider
    Curran Terrie

    Director of Arcutis Biotherapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ARQT insider trading history →

Related articles

AUG 5
$ARQTHigh

Arcutis Biotherapeutics, Inc. (ARQT): Results of Operations and Financial Condition

Arcutis Biotherapeutics, Inc. (ARQT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update • Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q2 revenues of $129.9 million, +59% versus Q2 of 2025, and +23% versus Q1 of 2026, driven primarily by strong demand grow

SEC EDGAR 8-K6 min
JUL 8
$ARQTMedAI 8/10

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

Arcutis Biotherapeutics (Nasdaq: ARQT) said the FDA accepted its supplemental NDA for ZORYVE (roflumilast) cream 0.05% to expand use for mild to moderate atopic dermatitis in infants aged 3 to 24 months. The FDA set a PDUFA target action date of Feb. 23, 2027. Data cited include Phase 2 INTEGUMENT-INFANT (101 infants) and Phase 1 PK (19 infants).

manilatimes.net5 min
AUG 28
Low

DST Global Advisors Ltd sold $38.6M of CHYM (indirect holdings)

DST Global Advisors Ltd sold 1,168,667 indirectly-held shares of Chime Financial, Inc. (CHYM) at $33.04 ($38.61M total) across 7 trades on 2026-08-26. Filed jointly with DST Global VI, L.P. (10% owner), DST Global VII, L.P. (10% owner), DST Investments XXI, L.P. (10% owner), DSTG VI Investments, L.P. (10% owner), DSTG VI Investments-A, L.P. (10% owner), DSTG VII Investments-1, L.P. (10% owner), DSTG VII Investments-4, L.P. (10% owner), DST Managers VI Ltd (10% owner) and DST Managers VII Ltd (10% owner).

SEC EDGAR1 min
Curran Terrie sold $956K of ARQT — alphai